Trevi Therapeutics Inc Total Liabilities
Trevi Therapeutics Inc total liabilities. Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has total liabilities worth $9.01 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Trevi Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Trevi Therapeutics Inc (2016–2025)
Total liabilities of Trevi Therapeutics Inc from 2016 to 2025. This chart illustrates how Trevi Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Trevi Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Trevi Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Trevi Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WG Tech JiangXi Co Ltd
SHG:603773
|
China | CN¥3.17 Billion |
|
Arena Star Group Ltd
TA:ARNA
|
Israel | ILA795.14 Million |
|
Netstreit Corp
NYSE:NTST
|
USA | $1.30 Billion |
|
Emami Limited
NSE:EMAMILTD
|
India | Rs9.14 Billion |
|
AOZORA BANK LTD ADR/20
F:AON0
|
Germany | €8.11 Trillion |
|
KCC Corporation
KO:002380
|
Korea | ₩8.98 Trillion |
|
Midera Food Processing Inc
NASDAQ:MFP
|
USA | $621.50 Million |
|
CETC Energy Joint Stock Co Ltd
SHG:600877
|
China | CN¥463.01 Million |
Liability Composition Analysis (2016–2025)
This chart breaks down Trevi Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Trevi Therapeutics Inc (TRVI) total assets.
Liquidity & Leverage Metrics
Trevi Therapeutics Inc Total Liabilities Ratios Explained
Trevi Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 37.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Trevi Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Trevi Therapeutics Inc (2016–2025)
The table below shows the annual total liabilities of Trevi Therapeutics Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $10.20 Million | -9.43% |
| 2024-12-31 | $11.26 Million | +64.18% |
| 2023-12-31 | $6.86 Million | -55.93% |
| 2022-12-31 | $15.56 Million | -27.31% |
| 2021-12-31 | $21.40 Million | +7.81% |
| 2020-12-31 | $19.85 Million | +263.80% |
| 2019-12-31 | $5.46 Million | +71.46% |
| 2018-12-31 | $3.18 Million | -57.29% |
| 2017-12-31 | $7.45 Million | -71.15% |
| 2016-12-31 | $25.82 Million | -- |
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction i… Read more